alanine has been researched along with Coronary Heart Disease in 44 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The 2 populations studied were as follows: (1) a cross-sectional study of 703 acute coronary syndrome (ACS) patients with myocardial infarction (MI) and unstable angina, and (2) a prospective study of 924 Caucasian patients from the OPUS (Orbofiban in Patients with Unstable coronary Syndromes)-TIMI-16 trial of the oral GPIIb/IIIa antagonist orbofiban." | 5.10 | Genetic variability in the extracellular matrix as a determinant of cardiovascular risk: association of type III collagen COL3A1 polymorphisms with coronary artery disease. ( Fitzgerald, A; Fitzgerald, DJ; Muckian, C; O'Byrne, A; O'Neill, A; Shields, DC, 2002) |
| " Our aim was to investigate the frequency of the alanine (Ala) 54Thr polymorphism of the FABP2 gene in patients with coronary heart disease (CHD), and the association between the polymorphism and the markers of metabolic syndrome, serum lipid levels and the fatty acid profile of serum lipids." | 3.71 | Variation in the fatty acid binding protein 2 gene is not associated with markers of metabolic syndrome in patients with coronary heart disease. ( Erkkilä, AT; Laakso, M; Lehto, S; Lindi, V; Pyörälä, K; Uusitupa, MI, 2002) |
| "Major or severe bleeding (but not intracranial hemorrhage) was higher with orbofiban; it occurred in 2." | 2.69 | Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. ( Alexander, JC; Anders, RJ; Berink, P; Braunwald, E; Cannon, CP; Caspi, A; Charlesworth, A; Langer, A; Lopez-Sendon, J; McCabe, CH; Skene, A; Toman, J; Wilcox, RG, 2000) |
| " Joint analysis of rs1801282-C, rs1063539-G, and rs1884614-T risk alleles showed an additive dosage effect (P for trend=0." | 1.38 | Association of the PPARG Pro12Ala polymorphism with type 2 diabetes and incident coronary heart disease in a Hong Kong Chinese population. ( Chan, JC; Germer, S; Ho, JS; Ma, RC; Martin, M; Ng, MC; So, WY; Tam, CH, 2012) |
| "Ranolazine was given as an intravenous bolus followed by continuous infusion; the mean total dose was 32." | 1.30 | Effects of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease. ( Bagger, JP; Bøtker, HE; Nielsen, TT; Thomassen, A, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (38.64) | 18.7374 |
| 1990's | 8 (18.18) | 18.2507 |
| 2000's | 17 (38.64) | 29.6817 |
| 2010's | 2 (4.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baumgartner, FJ | 1 |
| Barrio, JR | 1 |
| Henze, E | 1 |
| Schelbert, HR | 1 |
| MacDonald, NS | 1 |
| Phelps, ME | 1 |
| Kuhl, DE | 1 |
| Regieli, JJ | 1 |
| Jukema, JW | 1 |
| Doevendans, PA | 1 |
| Zwinderman, AH | 1 |
| van der Graaf, Y | 1 |
| Kastelein, JJ | 1 |
| Grobbee, DE | 1 |
| Gao, H | 1 |
| Zhang, Z | 1 |
| Zhang, J | 1 |
| Zhao, N | 1 |
| Li, Q | 1 |
| Bai, M | 1 |
| Ho, JS | 1 |
| Germer, S | 1 |
| Tam, CH | 1 |
| So, WY | 1 |
| Martin, M | 1 |
| Ma, RC | 1 |
| Chan, JC | 1 |
| Ng, MC | 1 |
| Muckian, C | 2 |
| Fitzgerald, A | 1 |
| O'Neill, A | 1 |
| O'Byrne, A | 1 |
| Fitzgerald, DJ | 2 |
| Shields, DC | 3 |
| Erkkilä, AT | 1 |
| Lindi, V | 1 |
| Lehto, S | 1 |
| Pyörälä, K | 1 |
| Laakso, M | 1 |
| Uusitupa, MI | 1 |
| de Lemos, JA | 3 |
| Morrow, DA | 3 |
| Sabatine, MS | 4 |
| Murphy, SA | 3 |
| Gibson, CM | 1 |
| Antman, EM | 1 |
| McCabe, CH | 4 |
| Cannon, CP | 7 |
| Braunwald, E | 5 |
| Cotter, G | 1 |
| Michowitz, Y | 1 |
| Kaluski, E | 1 |
| Charlesworth, A | 2 |
| Milo, O | 1 |
| Bentley, J | 1 |
| Blatt, A | 1 |
| Krakover, R | 1 |
| Zimlichman, R | 1 |
| Reisin, L | 1 |
| Marmor, A | 1 |
| Lewis, B | 1 |
| Vered, Z | 1 |
| Caspi, A | 2 |
| Tan, JH | 1 |
| Low, PS | 1 |
| Tan, YS | 1 |
| Tong, MC | 1 |
| Saha, N | 1 |
| Yang, H | 1 |
| Heng, CK | 1 |
| Rifai, N | 2 |
| Ayanian, S | 1 |
| Obeid, OA | 1 |
| Atar, S | 1 |
| Rosanio, S | 1 |
| Uretsky, BF | 1 |
| Birnbaum, Y | 1 |
| März, W | 1 |
| Seelhorst, U | 1 |
| Wellnitz, B | 1 |
| Tiran, B | 1 |
| Obermayer-Pietsch, B | 1 |
| Renner, W | 1 |
| Boehm, BO | 1 |
| Ritz, E | 1 |
| Hoffmann, MM | 1 |
| Scirica, BM | 1 |
| Murphy, S | 1 |
| Wiviott, SD | 1 |
| Thomassen, AR | 2 |
| Nielsen, TT | 8 |
| Bagger, JP | 8 |
| Henningsen, P | 6 |
| Thomassen, A | 6 |
| Thuesen, L | 1 |
| Fréminet, A | 1 |
| Leclerc, L | 1 |
| McNulty, PH | 1 |
| Sinusas, AJ | 1 |
| Shi, CQ | 1 |
| Dione, D | 1 |
| Young, LH | 1 |
| Cline, GC | 1 |
| Shulman, GI | 1 |
| Gallagher, PM | 1 |
| Meleady, R | 1 |
| Tan, KS | 1 |
| McMaster, D | 1 |
| Rozen, R | 1 |
| Evans, A | 1 |
| Graham, IM | 1 |
| Whitehead, AS | 1 |
| Bøtker, HE | 1 |
| Ringel, J | 1 |
| Engeli, S | 1 |
| Distler, A | 1 |
| Sharma, AM | 1 |
| Ferguson, JJ | 1 |
| Wilcox, RG | 1 |
| Langer, A | 1 |
| Berink, P | 1 |
| Lopez-Sendon, J | 1 |
| Toman, J | 1 |
| Anders, RJ | 1 |
| Alexander, JC | 1 |
| Skene, A | 1 |
| Jang, IK | 1 |
| Chew, DP | 2 |
| Bhatt, DL | 2 |
| Sapp, S | 1 |
| Topol, EJ | 1 |
| Schneider, J | 1 |
| Kreuzer, J | 1 |
| Hamann, A | 1 |
| Nawroth, PP | 1 |
| Dugi, KA | 1 |
| Fitzgerald, AP | 1 |
| O'Neill, PA | 1 |
| Kenny, D | 1 |
| Moran, B | 1 |
| Byrne, CE | 1 |
| Brodan, V | 1 |
| Fabián, J | 1 |
| Andĕl, M | 1 |
| Tomková, D | 1 |
| Mudge, GH | 1 |
| Mills, RM | 1 |
| Taegtmeyer, H | 1 |
| Gorlin, R | 1 |
| Lesch, M | 1 |
| Lewandowski, ED | 1 |
| Johnston, DL | 1 |
| Roberts, R | 1 |
| Pisarenko, OI | 4 |
| Studneva, IM | 3 |
| Shul'zhenko, VS | 1 |
| Khlopkov, VN | 1 |
| Novikov, ID | 1 |
| Kapel'ko, VI | 1 |
| Baranov, AV | 1 |
| Aleshin, OI | 1 |
| Pomerantsev, EA | 1 |
| Nikolaeva, LF | 1 |
| Savchenko, AP | 1 |
| Pavlov, NA | 1 |
| Novikova, EB | 2 |
| Serebriakova, LI | 1 |
| Tskitishvili, OV | 2 |
| Ivanov, VE | 2 |
| Serebryakova, LI | 1 |
| Pisarenko, O | 1 |
| Studneva, I | 1 |
| Khlopkov, V | 1 |
| Schaffer, SW | 1 |
| Allo, S | 1 |
| Mozaffari, M | 1 |
| Chazov, EI | 1 |
| Smirnov, VN | 2 |
| Mazaev, AV | 2 |
| Asafov, GB | 2 |
| Degtiar', VG | 1 |
| Chazov, E | 1 |
| Gukowski, DU | 1 |
| Krikov, VI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III Study of Intravenous Glutamate Infusion for Metabolic Protection of the Heart in Surgery for Unstable Coronary Artery Disease[NCT00489827] | Phase 3 | 865 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer[NCT03943966] | 73 participants (Actual) | Interventional | 2019-11-11 | Completed | |||
| Phase III Study of Metabolic Intervention With Glutamate in Coronary Surgery II[NCT02592824] | Phase 3 | 321 participants (Actual) | Interventional | 2015-11-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients with atrial fibrillation recorded postoperatively (NCT00489827)
Timeframe: Hospital stay
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 147 |
| Saline Infusion | 152 |
ICU duration of stay (hours) (NCT00489827)
Timeframe: ICU stay
| Intervention | hours (Median) |
|---|---|
| Intravenous Glutamate | 21 |
| Saline Infusion | 21 |
(NCT00489827)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 31 |
| Saline Infusion | 25 |
Incidence of Postoperative stroke < 24 hours of surgery verifed by CT-scan (NCT00489827)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 4 |
| Saline Infusion | 6 |
Hemodynamic instability despite inotropes or need for IABP at the end of surgery in patients with severely reduced left ventricular ejection fraction (LVEF<0.40) (NCT00489827)
Timeframe: End of surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 1 |
| Saline Infusion | 5 |
maximum p-creatinine value recorded postoperatively < 30 days (NCT00489827)
Timeframe: 30 days
| Intervention | µmol/L (Mean) |
|---|---|
| Intravenous Glutamate | 106 |
| Saline Infusion | 106 |
Severe circulatory failure according to prespecified criteria as judged by a blinded endpoints committee in CCS class IV patients (NCT00489827)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 3 |
| Saline Infusion | 16 |
p-CK-MB postoperative day 1, p-troponin-T postoperative day 3 (NCT00489827)
Timeframe: perioperative
| Intervention | µg/L (Median) | |
|---|---|---|
| CK-MB day 1 | Troponin-T day 3 | |
| Intravenous Glutamate | 14 | 0.27 |
| Saline Infusion | 14 | 0.24 |
Mixed venous oxygen saturation (SvO2) measured at weaning from cardiopulmonary bypass and on arrival to ICU (NCT00489827)
Timeframe: Until arrival to ICU
| Intervention | percentage of saturated hemoglobin (Mean) | |
|---|---|---|
| SvO2 at weaning from CPB | SvO2 on arrival to ICU | |
| Intravenous Glutamate | 72.0 | 65.0 |
| Saline Infusion | 72.2 | 64.9 |
Postoperative mortality was defined as mortality within 30 days of surgery. (NCT02592824)
Timeframe: up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate Infusion | 1 |
| Intravenous Saline Infusion | 6 |
suspected unexpected serious adverse reaction (NCT02592824)
Timeframe: within 24 hours from infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate Infusion | 0 |
| Intravenous Saline Infusion | 0 |
"Postoperative stroke was defined as neurological or cognitive deficit with a cerebral injury verified on (Computed Tomography) CT-scan. All suspected cases of stroke underwent CT-scan.~Stroke within 24 h of surgery was defined as a stroke that occurred within 24 h of surgery or signs of a stroke, when first assessable in deeply sedated patients on a ventilator." (NCT02592824)
Timeframe: within 24 hours from surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate Infusion | 0 |
| Intravenous Saline Infusion | 4 |
"Postoperative increase of NT-proBNP reflects postoperative myocardial dysfunction sustained in association with surgery. NT-proBNP usually peaks on the third to fourth postoperative day after coronary artery bypass surgery.~In the first GLUTAMICS trial a good agreement between hemodynamic criteria for postoperative heart failure and postoperative NT-proBNP was found." (NCT02592824)
Timeframe: from the day before surgery to the third postoperative day
| Intervention | ng/L (Mean) |
|---|---|
| Intravenous Glutamate Infusion | 5390 |
| Intravenous Saline Infusion | 6452 |
"Postoperative increase of NT-proBNP reflects postoperative myocardial dysfunction sustained in association with surgery. NT-proBNP usually peaks on the third to fourth postoperative day after coronary artery bypass surgery.~Previous observations suggest a blunted effect of glutamate in diabetic hearts." (NCT02592824)
Timeframe: from preoperative level to the third postoperative day
| Intervention | ng/L (Mean) |
|---|---|
| Intravenous Glutamate Infusion | 4503 |
| Intravenous Saline Infusion | 6825 |
Postoperative NT-proBNP reflects postoperative myocardial dysfunction. (NCT02592824)
Timeframe: first postoperative day
| Intervention | ng/L (Mean) |
|---|---|
| Intravenous Glutamate Infusion | 4438 |
| Intravenous Saline Infusion | 4420 |
Postoperative NT-proBNP reflects postoperative myocardial dysfunction. (NCT02592824)
Timeframe: third postoperative day
| Intervention | ng/L (Mean) |
|---|---|
| Intravenous Glutamate Infusion | 8055 |
| Intravenous Saline Infusion | 8804 |
3 reviews available for alanine and Coronary Heart Disease
| Article | Year |
|---|---|
The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Alanine; Angioplasty, Balloon, Coronary; A | 2000 |
Oral glycoprotein IIb/IIIa antagonists in coronary artery disease.
Topics: Administration, Oral; Alanine; Benzamidines; Coronary Disease; Humans; Integrins; Oximes; Piperidine | 2001 |
Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.
Topics: Administration, Oral; Alanine; Aspirin; Benzamidines; Clinical Trials, Phase III as Topic; Coronary | 2001 |
6 trials available for alanine and Coronary Heart Disease
| Article | Year |
|---|---|
Genetic variability in the extracellular matrix as a determinant of cardiovascular risk: association of type III collagen COL3A1 polymorphisms with coronary artery disease.
Topics: Alanine; Alleles; Angina, Unstable; Collagen; Collagen Type III; Coronary Disease; Cross-Sectional S | 2002 |
Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes.
Topics: Acute Disease; Adult; Aged; Alanine; Biomarkers; Chemokine CCL2; Cohort Studies; Confounding Factors | 2003 |
Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysi
Topics: Aged; Alanine; Aspirin; Cerebrovascular Disorders; Coronary Disease; Double-Blind Method; Drug Thera | 2003 |
Clinical application of C-reactive protein across the spectrum of acute coronary syndromes.
Topics: Acute Disease; Aged; Alanine; Angina Pectoris; Angina, Unstable; C-Reactive Protein; Coronary Diseas | 2007 |
Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
Topics: Administration, Oral; Alanine; Anticoagulants; Aspirin; Coronary Disease; Double-Blind Method; Femal | 2000 |
The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists.
Topics: Alanine; Coronary Disease; Genotype; Glycoproteins; Hemorrhage; Humans; Myocardial Infarction; Myoca | 2002 |
35 other studies available for alanine and Coronary Heart Disease
| Article | Year |
|---|---|
13N-labeled L-amino acids for in vivo assessment of local myocardial metabolism.
Topics: Amino Acids; Animals; Citric Acid Cycle; Coronary Disease; Dogs; Half-Life; Myocardium; Nitrogen Rad | 1981 |
PPAR gamma variant influences angiographic outcome and 10-year cardiovascular risk in male symptomatic coronary artery disease patients.
Topics: Alanine; Amino Acid Substitution; Blood Pressure; Coronary Disease; Genetic Variation; Genotype; Hum | 2009 |
Association of LT-alpha Ala252Gly gene polymorphism and the genetic predisposition of coronary heart disease in Chinese.
Topics: Alanine; Asian People; Case-Control Studies; China; Coronary Disease; Female; Genetic Predisposition | 2010 |
Association of the PPARG Pro12Ala polymorphism with type 2 diabetes and incident coronary heart disease in a Hong Kong Chinese population.
Topics: Adult; Alanine; Amino Acid Substitution; Asian People; Case-Control Studies; Coronary Disease; Diabe | 2012 |
Variation in the fatty acid binding protein 2 gene is not associated with markers of metabolic syndrome in patients with coronary heart disease.
Topics: Adult; Aged; Alanine; Alleles; Blood Pressure; Body Mass Index; Carrier Proteins; Codon; Coronary Di | 2002 |
ABCA1 gene polymorphisms and their associations with coronary artery disease and plasma lipids in males from three ethnic populations in Singapore.
Topics: Alanine; Apolipoprotein A-I; Asian People; ATP Binding Cassette Transporter 1; ATP-Binding Cassette | 2003 |
Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes.
Topics: Acute Disease; Alanine; Biomarkers; Coronary Disease; Female; Humans; Immunoassay; Male; Middle Aged | 2003 |
Plasma amino acid concentrations in patients with coronary heart disease: a comparison between U.K. Indian Asian and Caucasian men.
Topics: Alanine; Asian People; Biomarkers; Blood Glucose; Coronary Disease; Cysteine; Feeding Behavior; Huma | 2005 |
Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial.
Topics: Acute Disease; Administration, Oral; Aged; Alanine; Anticoagulants; Aspirin; Coronary Disease; Femal | 2006 |
Alanine to serine polymorphism at position 986 of the calcium-sensing receptor associated with coronary heart disease, myocardial infarction, all-cause, and cardiovascular mortality.
Topics: Adult; Aged; Alanine; Calcium; Cause of Death; Coronary Angiography; Coronary Disease; Female; Genet | 2007 |
Myocardial exchanges of glutamate, alanine and citrate in controls and patients with coronary artery disease.
Topics: Aged; Alanine; Cardiac Pacing, Artificial; Citrates; Citric Acid; Coronary Disease; Fatty Acids, Non | 1983 |
Myocardial glutamate and alanine exchanges related to carbohydrate metabolism in patients with normal and stenotic coronary arteries.
Topics: Adult; Alanine; Carbohydrate Metabolism; Constriction, Pathologic; Coronary Disease; Fatty Acids, No | 1984 |
[Simultaneous use of carbohydrates and amino acids during total ischemia in the isolated rat heart (author's transl)].
Topics: Alanine; Amino Acids; Animals; Carbohydrate Metabolism; Coronary Disease; Lactates; Male; Myocardium | 1980 |
Glucose metabolism distal to a critical coronary stenosis in a canine model of low-flow myocardial ischemia.
Topics: Alanine; Animals; Coronary Disease; Coronary Vessels; Disease Models, Animal; Dogs; Endocardium; Fat | 1996 |
Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation.
Topics: Alanine; Alleles; Coronary Disease; DNA Mutational Analysis; Female; Gene Frequency; Genotype; Homoc | 1996 |
Effects of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease.
Topics: Acetanilides; Aged; Alanine; Angina Pectoris; Blood Pressure; Citric Acid; Coronary Circulation; Cor | 1997 |
Pro12Ala missense mutation of the peroxisome proliferator activated receptor gamma and diabetes mellitus.
Topics: Adult; Alanine; Amino Acid Substitution; Cholesterol; Codon; Coronary Disease; Diabetes Mellitus; Di | 1999 |
Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology.
Topics: Abciximab; Alanine; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibo | 1999 |
The proline 12 alanine substitution in the peroxisome proliferator--activated receptor-gamma2 gene is associated with lower lipoprotein lipase activity in vivo.
Topics: Aged; Alanine; Alleles; Coronary Disease; Deoxyribonuclease HindIII; Deoxyribonucleases, Type II Sit | 2002 |
Amino acid metabolism in the heart muscle in subjects with ischaemic heart disease at rest and during pacing.
Topics: Adult; Alanine; Amino Acids; Ammonia; Cardiac Pacing, Artificial; Coronary Disease; Humans; Lactates | 1978 |
Alterations of myocardial amino acid metabolism in chronic ischemic heart disease.
Topics: Adult; Alanine; Amino Acids; Coronary Circulation; Coronary Disease; Female; Glutamates; Humans; Lac | 1976 |
Cardiac metabolic effects of heparin differentiate between patients with normal and stenotic coronary arteries.
Topics: Alanine; Angina Pectoris; Cardiac Pacing, Artificial; Citrates; Coronary Disease; Fatty Acids, Nones | 1990 |
Effects of inosine on glycolysis and contracture during myocardial ischemia.
Topics: Alanine; Animals; Contracture; Coronary Disease; Glycolysis; In Vitro Techniques; Inosine; Lactates; | 1991 |
[Relation between the energy state of the myocardium and the release of products of anaerobic metabolism].
Topics: Adenosine Triphosphate; Alanine; Anaerobiosis; Animals; Bicarbonates; Buffers; Coronary Disease; Cre | 1990 |
Antianginal and cardiac metabolic effects of low-dose glucose infusion during pacing in patients with and without coronary artery disease.
Topics: Alanine; Angina Pectoris; Blood Glucose; Cardiac Pacing, Artificial; Citrates; Coronary Disease; Ele | 1989 |
Cardiac metabolic and hemodynamic effects of insulin in patients with coronary artery disease.
Topics: Alanine; Blood Glucose; Cardiac Catheterization; Citrates; Citric Acid; Coronary Disease; Drug Evalu | 1989 |
Features of myocardial metabolism of some amino acids and ammonia in patients with coronary artery disease.
Topics: Adult; Alanine; Amino Acids; Ammonia; Asparagine; Cardiac Pacing, Artificial; Coronary Disease; Eval | 1989 |
[Correction of contractile function and metabolism in canine ischemic myocardium due to exogenous glutamic acid].
Topics: Alanine; Ammonia; Animals; Coronary Disease; Dogs; Female; Glutamates; Glutamic Acid; Glutamine; Mal | 1985 |
Function and metabolism of dog heart in ischemia and in subsequent reperfusion: effect of exogenous glutamic acid.
Topics: Alanine; Ammonia; Animals; Aspartic Acid; Coronary Disease; Dogs; Female; Glutamates; Glutamic Acid; | 1985 |
Metabolism of the tricarboxylic acid cycle intermediates and related amino acids in ischemic guinea pig heart.
Topics: Adenosine Triphosphate; Alanine; Amino Acids; Animals; Citric Acid Cycle; Coronary Disease; Glutamat | 1987 |
Potentiation of myocardial ischemic injury by drug-induced taurine depletion.
Topics: Adenine Nucleotides; Alanine; Animals; beta-Alanine; Coronary Disease; Heart; Male; Myocardium; Phos | 1987 |
Altered global myocardial substrate preference at rest and during pacing in coronary artery disease with stable angina pectoris.
Topics: Adult; Alanine; Angina Pectoris; Cardiac Pacing, Artificial; Citrates; Coronary Disease; Fatty Acids | 1988 |
Whole blood versus plasma measurements of glutamate and alanine across the human myocardium.
Topics: Adult; Aged; Alanine; Blood; Cardiac Pacing, Artificial; Coronary Disease; Female; Glutamates; Human | 1987 |
[Coronary arterio-venous difference in the concentration of various products of nitrogen metabolism in man].
Topics: Adult; Alanine; Ammonia; Aorta; Arteriosclerosis; Coronary Disease; Coronary Vessels; Glutamates; Gl | 1972 |
Myocardial ammonia metabolism in patients with heart disease as revealed by coronary sinus catheterization study.
Topics: Adult; Alanine; Ammonia; Cardiac Catheterization; Cineangiography; Coronary Angiography; Coronary Di | 1973 |